Antibiotic Safety and Effectiveness in Premature Infants With Complicated Intraabdominal Infections
| Autor: | Gratias Mundakel, Gregory M. Sokol, Sherry E. Courtney, Daniel K. Benjamin, Joseph M. Bliss, Jörn-Hendrik Weitkamp, Mark L. Hudak, Gaurav Sharma, Jinson Erinjeri, Matthew A. Saxonhouse, Jamie Gao, P. Brian Smith, Christiane E.L. Dammann, Julie Debski, Gloria P Heresi, Catherine M. Bendel, Barry T. Bloom, C. Michael Cotten, Julie Autmizguine, Angelique E Boutzoukas, Adrian Lavery, Erin K. Zinkhan, Michael J. Smith, Susan R. Mendley, Christoph P. Hornik, Michael Cohen-Wolkowiez |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Intraabdominal infection medicine.drug_class Antibiotics Population Article 03 medical and health sciences 0302 clinical medicine 030225 pediatrics Internal medicine Medicine Humans 030212 general & internal medicine Prospective Studies education education.field_of_study Study drug business.industry Mortality rate Infant Newborn Gestational age Infant Confidence interval Anti-Bacterial Agents Clinical trial Infectious Diseases Treatment Outcome Pediatrics Perinatology and Child Health Intraabdominal Infections business Infant Premature |
| Zdroj: | Pediatr Infect Dis J |
| ISSN: | 1532-0987 |
| Popis: | BACKGROUND: In premature infants, complicated intra-abdominal infections (cIAIs) are a leading cause of morbidity and mortality. Although universally prescribed, the safety and effectiveness of commonly used antibiotic regimens has not been established in this population. METHODS: Infants ≤33 weeks gestational age and 4) 30 days after study drug completion. RESULTS: 180 infants (128 randomized [R], 52 non-randomized [NR]) were enrolled: 63 in group 1 (45 R, 18 NR), 47 in group 2 (41 R, 6 NR), and 70 in group 3 (42 R, 28 NR). Thirty-day mortality was 8%, 7%, and 9% in groups 1, 2, and 3, respectively. There were no differences in safety outcomes between antibiotic regimens. After adjusting for treatment group and gestational age, mortality rates through end of follow-up were 4.22 (95% confidence interval [CI] 1.39–12.13), 4.53 (95% CI 1.21–15.50), and 4.07 (95% CI 1.22–12.70) for groups 1, 2, and 3, respectively. CONCLUSIONS: Each of the antibiotic regimens are safe in premature infants with cIAI. CLINICAL TRIAL REGISTRATION: NCT0199499 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|